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DOI 10.1016/j.stem.2010.06.002Embryonic stem cells are pluripotent cells
derived from the inner cell mass of the
developing embryo that have the capacity
to differentiate into every cell type of the
adult (Evans and Kaufman, 1981; Martin,
1981; Martin and Evans, 1975; Thomson
et al., 1998). The generation of patient-
specific pluripotent cells is therefore an
important goal of regenerative medicine.
A major step to achieve this was the
recent discovery that ectopic expression
of defined transcription factors induces
pluripotency in somatic cells (Lowry
et al., 2008; Park et al., 2008b; Takahashi
et al., 2007; Yu et al., 2007). Until now, the
most common source from which to
derive human iPSCs has been skin fibro-
blasts (Lowry et al., 2008; Park et al.,
2008a, 2008b; Takahashi et al., 2007; Yu
et al., 2009). However, the requirement
for skin biopsies and the need to expand
fibroblast cells for several passages
in vitro represent a hurdle that must be
overcome to make iPSC technology
broadly applicable. Peripheral blood can
be utilized as an easily accessible source
of patient tissue for reprogramming. Here
we derived iPSCs from frozen human
peripheral blood samples. Some of the
iPSCs had rearrangements of the T cell
receptor (TCR), indicating that T cells
can be reprogrammed to pluripotency.
Recently, granulocyte colony stimu-
lating factor (G-CSF)-mobilized CD34+
blood cells have been used as a source
from which to derive iPSCs (Loh et al.,
2009). However, this requires the subcu-
taneous injection of G-CSF, a process
that can be applied only if the donor is in
good medical condition. Also, the nega-
tive effects of treatment of patients with
growth factors such as erythropoietin
(Miller et al., 2009) and G-CSF are still
being investigated. Of concern is the use
of G-CSF because this cytokine is20 Cell Stem Cell 7, July 2, 2010 ª2010 Elseva growth factor formyeloid cell precursors
(Touw and van de Geijn, 2007) and
because G-CSF treatment of patients
with severe congenital neutropenia
(SCN) can result in a truncated G-CSF
receptor allele and acute myeloid
leukemia transformation (Touw, 1997).
Derivation of iPSCs from peripheral
mononuclear blood cells would circum-
vent all these issues; in addition, periph-
eral blood is the most accessible adult
tissue and permits access to numerous
frozen samples already stored at blood
banks. Such samples could be expanded
in culture and reprogrammed to iPSCs,
which in turn allows researchers to study
the molecular mechanism underlying
blood and other disorders. We show
here the derivation of iPSC clones from
mature peripheral blood T and myeloid
cells.
Mononuclear (MNC) blood cells were
isolated from several donors by Ficoll-Hy-
paque density gradient centrifugation
(Ferrante and Thong, 1980; Vissers et al.,
1988). Samples were frozen and thawed
days to several months after freezing
and expanded in IL-7 or in G-CSF, GM-
CSF, IL-6, and IL-3 for 5 days. In our initial
experiments we used the FUW-M2rtTA
and the individual doxycycline-inducible
lentiviruses encoding Oct4, Sox2, c-
Myc, or Klf4 (Brambrink et al., 2008).
However, in ten independent experiments
we were not able to reprogram peripheral
blood cells with this system. One possi-
bility for failure to obtain iPSCs is that
peripheral blood cells are difficult to
infect, reducing the probability of obtain-
ing cells carrying the four factors as well
as the FUW-M2rtTA construct. Also, we
find that the efficiency of blood reprog-
ramming (0.001%–0.0002%) is approxi-
mately 10–50 times lower than that of
human fibroblast reprogramming.ier Inc.To increase the infection efficiency, we
used a doxycycline-inducible lentivirus
encoding all four factors Oct4, Klf4,
Sox2, and c-Myc from a polycistronic
expression cassette (pHAGE2-TetOmi-
niCMV-hSTEMCCA) (Sommer et al.,
2010). Blood cells were simultaneously in-
fected with a constitutively active lenti-
virus encoding the reverse tetracycline
transactivator (FUW-M2rtTA) (Hocke-
meyer et al., 2008) as well as the polycis-
tronic vector. Infected blood cells were
transferred onto feeder layers of mouse
embryonic fibroblasts (MEFs) and cul-
tured in the presence of IL-7 or G-CSF,
GM-CSF, IL-6, and IL-3 and 2 mg/ml doxy-
cycline (Dox) for an additional 4 days
(Figure 1A). At day 5 after Dox induction,
the cells were transferred to human ESC
medium containing 2 mg/ml Dox, and
25–40 days later colonies were picked
and expanded.
We obtained iPSC colonies from
several donors of different age (25–65
years) (Table S1 available online). We
found that cells cultured in the presence
of IL-7 expanded and reprogrammed
more efficiently than cells grown in the
presence of G-CSF, GM-CSF, IL-3, and
IL-6. Southern blot analyses probing for
M2rtTA vector integrations indicated that
several iPSC lines of donors 3
(Figure S1A) and 4 (and data not shown)
were derived from independent cells.
Colonies were expanded into stable,
Dox-independent iPSC lines that were
not dependent on exogenous factor
expression (Figure S1B). iPSCs that dis-
played the morphology characteristic of
human ESCs had a normal karyotype (Fig-
ure S1C) and stained positive for the plu-
ripotency markers Oct4, Nanog, and
Tra1-81 (Figure 1B). Blood-derived iPSCs
were cultured up to 35 passages and had
elongated telomeres as shown by
Figure 1. Characterization of Peripheral Blood-Derived iPSCs
(A) Schematic drawing demonstrating the strategy to derive iPSCs from human peripheral blood.
(B) Immunostaining for pluripotency markers Oct4, Nanog, and Tra1-81 in one representative T-iPSCs and M-iPSC line.
(C) Southern blot analyses showing that telomeres are elongated in T-iPSCs andMiPSCs compared to mononuclear (D1MNC, D3MNC) and myeloid (D3myeloid)
cells.
(D) Quantitative RT-PCR assay for expression analyses of mesodermal (Brachyury), endodermal (AFP), and ectodermal (NCAM) lineage markers in differentiated
embryoid bodies and iPSCs. Data are relative to GAPDH.
(E) Teratoma analysis from one representative T-iPSC and M-iPSC line.
(F) Methylation analyses of the Oct4 promoter region in human ESC, T-iPSC, M-iPSC, and peripheral blood cells.
See also Table S1 and Figure S1.
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TTAGGG repeat probe (Figure 1C; de
Lange, 1992).
To assess the in vitro differentiation
capacity of the iPSC lines, the cells were
differentiated into embryoid bodies (EBs).
Quantitative RT-PCR analyses of meso-
dermal (Brachyury), endodermal (AFP),
and ectodermal (NCAM) markers demon-
strated that all three lineage markers were
upregulated in the differentiated EBs as
compared to the undifferentiated iPSC
lines (Figure 1D). To evaluate their in vivo
differentiation potential, the iPSCs were
injected subcutaneously into NOD-SCID
mice and tumors were removed after
6–8 weeks. Histological analyses re-
vealed that cell types characteristic for
all three germ layers including ectoderm
(neural rosette, neural epithelium), meso-
derm (cartilage, bone), and endoderm
(intestinal epithelium) were present (Fig-
ure 1E), indicative of pluripotency.
Reactivation of Oct4 locus through de-
methylation of its promoter during reprog-
ramming is a hallmark of iPSCs.We there-
fore determined the methylation patterns
of the Oct4 promoter region in iPSCs
and peripheral blood cells. iPSCs had
mostly nonmethylated promoter regions
characteristic for the active Oct4 gene,
whereas peripheral blood samples
showed the expected highly methylated
promoter (Figure 1F). The results shown
in Figure 1 indicate that peripheral
blood-derived iPSCs are pluripotent and
show the molecular and morphological
characteristics of human ESCs.
T cell development involves sequential
genetic DNA rearrangements of the
T cell receptor (TCRD > TCRG > TCRB >
TCRA) or immunoglobulin loci (IGH > IGL
> IGK), respectively (Davis and Bjorkman,
1988; Kisielow and von Boehmer, 1995;
Rajewsky, 1996; Tonegawa, 1983). This
allowed us to retrospectively assess
whether the iPSCs were derived from
mature T cells (TCR gene rearrange-
ments), B cells (IG gene rearrangements),
or myeloid cells (no TCR/IG gene rear-
rangements). During normal develop-
ment, T cells mature in the thymus and
migrate into the periphery as fully differen-
tiated cells (Kisielow and von Boehmer,
1995). Detection of any TCR gene rear-
rangement in iPSCs derived from periph-
eral blood of healthy donors is, therefore,
indicative of a mature T cell. PCR anal-
yses were performed to detect potential22 Cell Stem Cell 7, July 2, 2010 ª2010 ElsevTCR delta (TCRD), TCR gamma (TCRG),
or TCR beta (TCRB) rearrangements via
TCR primer sets designed by the BI-
OMED-2 consortium (van Dongen et al.,
2003) and purchased from InVivoScribe
Technologies. The primer mixes target
conserved regions within the variable (V),
diversity (D), and joining regions (J) of
the TCRB, TCRD, or the V and J regions
of TCRG, respectively. In a clonal cell
population, amplification of this region
results in a PCR product within a predict-
able size range.
We identified bands within the valid
size range for TCRB (Figure 2A; Fig-
ure S1D) and/or TCRG (Figure 2B; Fig-
ure S1E) gene rearrangements for all
iPSC clones derived from donors 3 and
4. All clones analyzed tested negative
for TCRD rearrangements (Figure 2C
and data not shown). Sequencing anal-
yses further identified the specific nature
of productive TCRB and productive or
unproductive TCRG gene rearrange-
ments as shown in Figure 2D. Some
PCR conditions led to amplification of
additional bands inside and outside the
valid size range. We cloned numerous
PCR products that were in close prox-
imity to the expected size range and
confirmed that they reflect unspecific am-
plicons (data not shown).
One iPSC line (D1MiPS #1) derived in
IL-7 was negative in all TCR gene rear-
rangement assays (Figures S2A–S2C).
We therefore investigated whether this
clone originated from a B lymphocyte or
a myeloid cell. With the framework 1-3
primer sets (van Dongen et al., 2003), we
did not detect any IGH gene rearrange-
ments (Figure S2D), suggesting that this
clone may have originated from a myeloid
cell. As expected, the two iPSC clones
(D2MiPS #1 and #2) derived in the pres-
ence of G-CSF, GM-CSF, IL-3, and IL-6
tested negative in all TCR (Figures S2A–
S2C) or IGH gene (Figure S2D) rearrange-
ment assays, whereas one iPSC line
(D2TiPS#1) derived from the same donor
in IL-7 tested positive for TCRGgene rear-
rangement (Figure S2C). In summary, our
results indicate that iPSCs can be derived
from terminally differentiated adult
peripheral T cells.
Current protocols for reprogramming
human cells are based on skin fibroblasts,
keratinocytes, or G-CSF-mobilized
CD34+ cells (Loh et al., 2009; Park et al.,
2008b; Takahashi et al., 2007; Yu et al.,ier Inc.2009). Nuclear transfer and four factor-
mediated reprogramming experiments
have demonstrated that pluripotency
can be induced in terminally differentiated
mouse lymphocytes (Hanna et al., 2008;
Hochedlinger and Jaenisch, 2002; Hong
et al., 2009). Here, we show that human
peripheral blood T and myeloid cells
cultured in IL-7 or G-CSF, GM-CSF, IL-
3, and IL-6 can be reprogrammed to
a pluripotent state via a polycistronic
vector encoding Oct4, Klf4, Sox2, and
c-Myc. Because of sequential DNA rear-
rangements of TCR or IG genes during
lymphocyte development (Kisielow and
von Boehmer, 1995; Rajewsky, 1996),
we were able to retrospectively assess
that the majority of iPSCs were derived
from peripheral blood T cells. Two clones
obtained in G-CSF, GM-CSF, IL-3, and IL-
6 and one clone derived in IL-7 tested
negative for TCR and IG gene rearrange-
ments, suggesting that these iPSCs origi-
nated from myeloid cells. Proliferation of
somatic cells is an important parameter
of reprogramming (Hanna et al., 2009),
which is consistent with the higher re-
programming efficiency of T lymphoyctes
as compared to myeloid cells because
T cells have higher proliferation rates
and better long-term growth potential
in vitro than myeloid cells.
Our study demonstrates that peripheral
blood can be utilized as an easily acces-
sible source of patient tissue for reprog-
ramming without the need to extensively
maintain cell cultures prior to reprogram-
ming experiments. This is an important
step to make the iPSC technology more
broadly applicable. Importantly, reprog-
ramming of peripheral blood samples
will permit access to numerous frozen
samples already stored at blood banks.
These samples are often of restricted
use for research, because limited cell
numbers do not allow experimental
manipulations. This is particularly relevant
if the patient is deceased and new mate-
rial cannot be obtained. Generation of
iPSCs from such samples could provide
cell numbers large enough to retrospec-
tively screen for genetic factors and
to study molecular mechanisms under-
lying myeloid and lymphoid blood disor-
ders. The culture conditions used in the
current study primarily expanded T
lymphocytes and myeloid cells and are
probably the reason why B lymphocyte
iPSCs were not derived. To expand B
Figure 2. Analyses of TCR Gene Rearrangements in T-iPSCs
(A) PCR analyses of TCRB Vb-Jb gene rearrangements in six iPSC lines derived from peripheral blood of donor 4. PCR products within the indicated valid size
range were cloned and sequenced.
(B) PCR analyses of TCRGVg-Jg gene rearrangements in six iPSC lines derived from donor 4. PCR products within the indicated valid size rangewere cloned and
sequenced.
(C) PCR analyses showing that all iPSC clones from donor 4 tested negative for Vd-Jd TCRD gene rearrangements.
(D) Sequencing analyses of PCR products obtained in (A) and (B). Shown are productive TCRB and productive (D4 #4) and unproductive (D4 #1) TCRG gene
rearrangements in selected T-iPSC clones of donor 4. Genomic DNA from human ESC line BGO2 was used as negative control in all PCR assays; clonal positive
controls were purchased from InVivoScribe Technologies.
See also Table S1 and Figures S1 and S2.
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reprogramming process cells would
need to be cultured in IL-4/CD40 ligandin order to promote B cell survival and
expansion (von Bergwelt-Baildon et al.,
2002). In summary, our study allows re-Cell Stemprogramming of the most easily available
adult lineage and provides a protocol to
access samples stored at blood banks.Cell 7, July 2, 2010 ª2010 Elsevier Inc. 23
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